References and further reading
- Fisher B, Costantino J, Redmond C, Margolese R, Dimitrov N, Wolmark N, Wickerham D.L, Deutsch M, Ore L, Mamounas E, PoIler W, Kavanah M. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581–1586
- Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA. Radiotherapy in breast-conserving treat-ment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853—EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355: 528–533
- Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. UK Coordinating Committee on Cancer Research (UKCCCR) ductal carcinoma in situ (DCIS) working party on behalf of DCIS trialists in the UK, Australia and New Zealand radiotherapy and Tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet 2003;362:95–102
- Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340: 1455–1461
- Baxter NN, Vimig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443–448